Catalyst Pharmaceuticals (CPRX) News Today $22.78 +0.12 (+0.53%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Up 12.5% in DecemberCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 6,680,000 shares, a growth of 12.5% from the December 15th total of 5,940,000 shares. Based on an average daily trading volume, of 975,100 shares, the short-interest ratio is currently 6.9 days.January 18 at 4:38 PM | marketbeat.com61,009 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Redhawk Wealth Advisors Inc.Redhawk Wealth Advisors Inc. acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 61,009 shares of the biopharmaceutical compJanuary 16, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)JPMorgan Chase & Co. boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 9.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 408,261 shares of the biopharmaceuticaJanuary 15, 2025 | marketbeat.comCatalyst Pharma (CPRX) Receives a Buy from Truist FinancialJanuary 14, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gainsJanuary 13, 2025 | marketwatch.comCatalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSEJanuary 13, 2025 | seekingalpha.comHC Wainwright Raises Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $35.00January 13, 2025 | americanbankingnews.comCatalyst Pharmaceuticals' (CPRX) Buy Rating Reiterated at Bank of AmericaJanuary 12, 2025 | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Stock Rating Lowered by StockNews.comStockNews.com lowered shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday.January 11, 2025 | marketbeat.comCatalyst Pharmaceuticals price target raised to $35 from $30 at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals price target raised to $31 from $29 at OppenheimerJanuary 10, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright raised their target price on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a research report on Friday.January 10, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Teva PharmaceuticalsJanuary 9, 2025 | finanznachrichten.deCatalyst settlement with Teva a positive event, says BofAJanuary 9, 2025 | markets.businessinsider.comBank of America Reaffirms Buy Rating for Catalyst Pharmaceuticals (NASDAQ:CPRX)Bank of America reissued a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday.January 9, 2025 | marketbeat.comCatalyst Pharmaceuticals Secures Patent Victory: Analyst Reaffirms Buy Rating with 58.7% Upside PotentialJanuary 9, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals reports settlement of Firdapse patent litigation with TevaJanuary 8, 2025 | markets.businessinsider.comCatalyst stock climbs 15% on Firdapse litigation settlementJanuary 8, 2025 | msn.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Trading Up 13% - Should You Buy?Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 13% Higher - Still a Buy?January 8, 2025 | marketbeat.comCatalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva PharmaceuticalsJanuary 8, 2025 | globenewswire.comCatalyst Pharmaceuticals management to meet with TruistJanuary 8, 2025 | markets.businessinsider.comOliver Luxxe Assets LLC Purchases 35,225 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Oliver Luxxe Assets LLC boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 103.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 69,250 shares of the biopharmaceutical company's stJanuary 7, 2025 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to "Strong-Buy" RatingStockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday.January 3, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of "Buy" by AnalystsCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has received a consensus recommendation of "Buy" from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1January 1, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. trimmed its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 9.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 575,953 shares of the biopharmaceutical company's stock after seDecember 30, 2024 | marketbeat.comSanctuary Advisors LLC Purchases Shares of 31,040 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Sanctuary Advisors LLC acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 31,040 shares of the biopharmDecember 25, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Cut to Buy at StockNews.comStockNews.com downgraded Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday.December 24, 2024 | marketbeat.comIs Catalysts Pharmaceuticals, Inc. (CPRX) the Best Performing Biotech Stock in 2024?December 23, 2024 | msn.comIs Catalysts Pharmaceuticals, Inc. (CPRX) the Best Performing Biotech Stock in 2024?December 23, 2024 | msn.comGeode Capital Management LLC Reduces Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Geode Capital Management LLC lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,664,424 shares of the biopharmaceutical company'December 23, 2024 | marketbeat.comBank of America Securities Sticks to Its Buy Rating for Catalyst Pharma (CPRX)December 22, 2024 | markets.businessinsider.comBarclays PLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Barclays PLC raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 129.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 248,458 shares of the biopharmaceutical company's stock afterDecember 21, 2024 | marketbeat.comWellington Management Group LLP Makes New $1.19 Million Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Wellington Management Group LLP purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 59,584 shares of the biopharmacDecember 20, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Significant Increase in Short InterestCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 6,090,000 shares, an increase of 7.2% from the November 15th total of 5,680,000 shares. Based on an average trading volume of 957,100 shares, the days-to-cover ratio is presently 6.4 days.December 17, 2024 | marketbeat.comCatalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 16, 2024 | globenewswire.comState Street Corp Sells 347,968 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)State Street Corp lowered its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,685,330 shares of the biDecember 16, 2024 | marketbeat.comCatalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gainsDecember 14, 2024 | marketwatch.comJane Street Group LLC Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Jane Street Group LLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 245.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 401,908 shares of the biopharmaceuticaDecember 14, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $1,096,500.00 in StockDecember 12, 2024 | insidertrades.comJanus Henderson Group PLC Has $7.16 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Janus Henderson Group PLC reduced its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 83.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 360,191 shares of the biopharmDecember 10, 2024 | marketbeat.comCatalyst Pharmaceuticals: Agamree Is Its Key To A Sustainable FutureDecember 9, 2024 | seekingalpha.comVerition Fund Management LLC Buys 43,447 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Verition Fund Management LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 180.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,502 shares of the biopharmaceutical company's stoDecember 8, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of "Buy" from BrokeragesCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has been given a consensus recommendation of "Buy" by the seven analysts that are currently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year pDecember 7, 2024 | marketbeat.comWhy Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?December 6, 2024 | finance.yahoo.comBNP Paribas Financial Markets Increases Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)BNP Paribas Financial Markets boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 206.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 153,250 shares of the biopharmaceutical company's stockDecember 6, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $23.22 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Charles Schwab Investment Management Inc. raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 4.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,167,743 shares of the biopharmaceutical company's stocDecember 6, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Position Reduced by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 21.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,057,390 shares oDecember 5, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest UpdateCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 5,680,000 shares, a decline of 5.5% from the October 31st total of 6,010,000 shares. Based on an average daily volume of 946,800 shares, the short-interest ratio is currently 6.0 days.December 3, 2024 | marketbeat.comWalleye Capital LLC Invests $4.94 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Walleye Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 248,288 shares of the biopharmaceutical cDecember 2, 2024 | marketbeat.comMartingale Asset Management L P Buys New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Martingale Asset Management L P purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 87,077 shares of the biopharmaceutical companDecember 2, 2024 | marketbeat.com Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Media Mentions By Week CPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼0.760.44▲Average Medical News Sentiment CPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼45▲CPRX Articles Average Week Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PCVX News QGEN News ROIV News ASND News BPMC News RVMD News BBIO News LNTH News LEGN News ELAN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CPRX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
